子宫平滑肌肉瘤:流行病学、当代治疗策略及子宫旋切术的影响
子宫平滑肌肉瘤占所有子宫恶性肿瘤的1%,却导致相当比例的子宫癌死亡。手术是所有软组织肉瘤的主要治疗手段,但该病术前诊断困难,易与良性子宫肌瘤混淆。近年因旋切术和肌瘤剔除术可能在隐匿性子宫肉瘤中无意使用而引发担忧。肿瘤侵袭性强且对化疗放疗相对抵抗,早期和晚期患者均缺乏有效延长生存或治愈的手段。诊断时分期仍是生存最强决定因素。吉西他滨/多西他赛和多柔比星仍是晚期或复发疾病最有效方案,但现有细胞毒方案不足,5年疾病特异性生存率<30%。帕唑帕尼、曲贝替定和奥拉单抗为FDA批准的靶向药物,芳香化酶抑制剂和免疫治疗正在研究中。本综述批判性评价当代手术和药物治疗、靶向治疗作用及子宫旋切术对妇科手术实践的影响。
要点
- 子宫平滑肌肉瘤占子宫恶性肿瘤1%,术前难以与良性肌瘤鉴别。
- 诊断时分期仍是生存最强决定因素,预测模型可能提供更准确预后。
- 吉西他滨/多西他赛和多柔比星为晚期或复发疾病最活跃方案。
核心结论
- 子宫平滑肌肉瘤侵袭性强且对化疗放疗相对抵抗,早期和晚期患者均难以实现长期生存或治愈。
- 诊断时分期仍是生存最强决定因素,预测模型可能提供更准确预后。
- 吉西他滨/多西他赛和多柔比星仍是晚期或复发疾病最活跃方案,但现有细胞毒方案不足,5年疾病特异性生存率<30%。
- 帕唑帕尼、曲贝替定和奥拉单抗为FDA批准的在子宫及其他平滑肌肉瘤中有活性的靶向药物,芳香化酶抑制剂和免疫治疗正在研究中。
研究设计与样本
- 本文为综述,对当代手术和药物治疗子宫平滑肌肉瘤、靶向治疗作用及子宫旋切术对妇科手术实践影响的文献进行批判性评价。
主要发现
- 子宫平滑肌肉瘤占所有子宫恶性肿瘤的1%,但导致相当比例的子宫癌死亡。
- 子宫平滑肌肉瘤术前诊断困难,可模仿良性子宫肌瘤外观。
- 近年因外科医生在隐匿性子宫肉瘤中无意使用子宫旋切术和肌瘤剔除术而担忧增加。
- 现有细胞毒方案不足,5年疾病特异性生存率<30%。
- 帕唑帕尼、曲贝替定和奥拉单抗为FDA批准的有活性靶向药物,芳香化酶抑制剂和免疫治疗正在研究中。
临床怎么用
- 手术是所有软组织肉瘤包括子宫平滑肌肉瘤的主要治疗手段。
- 吉西他滨/多西他赛和多柔比星仍是晚期或复发疾病最活跃方案。
- 帕唑帕尼、曲贝替定和奥拉单抗为FDA批准的有活性靶向药物。
- 芳香化酶抑制剂和免疫治疗正在研究中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leiomyosarcoma, a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. Surgery is considered the mainstay of treatment for all soft tissue sarcomas, including uterine variants. However, uterine leiomyosarcoma is challenging to diagnose preoperatively and can mimic the appearance of benign uterine leiomyomas. Recently, concerns have grown in this regard, as surgeons have utilized uterine morcellation and myomectomy procedures unknowingly in the setting of occult uterine sarcoma. Because of aggressive tumor biology and relative chemotherapy and radiotherapy resistance, efficacious therapies to achieve prolonged survival or cure in those with both early and advanced-stage uterine leiomyosarcoma have been elusive. The strongest determinant of survival remains stage at diagnosis, though prediction models may provide a more accurate prognosis. Given the aggressive nature of this sarcoma subtype, novel early detection strategies and targeted therapies are the focus of several recently published and ongoing studies. While gemcitabine/docetaxel and doxorubicin remain the most active regimens in the treatment of advanced or recurrent disease, currently available cytotoxic regimens remain inadequate, with 5-year disease-specific survival of <30%. Pazopanib, trabectedin and olaratumab, are FDA-approved, targeted therapies with activity in uterine and other leiomyosarcomas, while aromatase inhibitors and immunotherapies are under active investigation. This review provides a critical appraisal of the literature regarding the contemporary surgical and medical management of uterine leiomyosarcoma, the role of targeted therapies, and the implications of uterine morcellation on gynecologic surgical practice.
引用
- Ricci S, Stone RL, Fader AN, et al. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017. PMID: 28209496. doi:10.1016/j.ygyno.2017.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。